Effects of an Immunomodulatory Therapy and Chondroitinase After Spinal Cord Hemisection Injury

Author:

Grosso Matthew J.12,Matheus Virgilio3,Clark Megan,van Rooijen Nico4,Iannotti Christopher A.5,Steinmetz Michael P.67

Affiliation:

1. Center for Spine Health, Department of Neurological Surgery, Cleveland Clinic, Cleveland, Ohio

2. Department of Neuroscience, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio

3. Southeastern Brain and Spine, Lumberton North Carolina

4. Department of Cell Biology & Immunology, Faculty of Medicine, Free University Medical Center, Amsterdam, Netherlands

5. Arizona Neurosurgery and Spine Specialists, Phoenix Arizona

6. Department of Neurological Surgery, Case Western Reserve University School of Medicine, Cleveland, Ohio

7. MetroHealth Medical Center, Cleveland, Ohio

Abstract

Abstract BACKGROUND: Individually, immunomodulatory therapy and chondroitinases have demonstrated neuroprotective and potential neuroregenerative effects following spinal cord injury. OBJECTIVE: To investigate the therapeutic potential of combined immunomodulatory and chondroitin sulfate-glycosaminoglycan degradation therapy in spinal cord injury. METHODS: A combined immunomodulatory treatment using (1) liposome-encapsulated clodronate (selectively depletes peripheral macrophages), and (2) rolipram (a selective type 4 phosphodiesterase inhibitor), along with the chondroitin sulfate proteoglycan-glycosaminoglycan-degrading enzyme, chondroitinase ABC (ChABC), was assessed for its potential to promote axonal regrowth and improve locomotor recovery following midthoracic spinal cord hemisection injury in adult rats. RESULTS: We demonstrate that combined treatment with liposomal clodronate, rolipram, and ChABC attenuates macrophage accumulation at the site of injury, reduces axonal die-back of injured dorsal column axons, and produces the greatest improvement in locomotor recovery at 6 weeks postinjury compared with controls and noncombined therapy. Anterograde and retrograde tracing revealed that delivery of clodronate, rolipram, and ChABC did not promote substantial axonal regeneration through the site of injury, although the treatment did limit the extent of axonal die-back. Histological assessments revealed that combined treatment with clodronate/rolipram and/or ChABC resulted in a significant reduction in lesion size and cystic cavitation in comparison with injured controls. Combined clodronate, rolipram, and ChABC treatment reduced the accumulation of macrophages within the injured spinal cord 7 weeks after injury. CONCLUSION: The present data suggest that delivery of an immunomodulatory therapy consisting of clodronate and rolipram, in combination with ChABC, reduces axonal injury and enhances neuroprotection, plasticity, and hindlimb functional recovery after hemisection spinal cord injury in adult rats.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Clinical Neurology,Surgery

Reference49 articles.

1. Observations on the pathology of human spinal cord injury;Bunge;A review and classification of 22 new cases with details from a case of chronic cord compression with extensive focal demyelination. Adv Neurol,1993

2. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms;Tator;J Neurosurg,1991

3. Macrophages and inflammatory damage in spinal cord injury;Blight,1992

4. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury;Popovich;Exp Neurol,1999

5. Degeneration and regeneration of axons in the lesioned spinal cord;Schwab;Physiol Rev,1996

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3